Cagrilintide Mechanism of Action
How a long-acting analog of the hormone amylin acts on brainstem appetite circuits, and why that pathway is studied as a complement to GLP-1 receptor agonism.
Amylin: The Hormone Cagrilintide Is Built On
Amylin is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells after a meal. In research it is associated with three linked effects: it slows gastric emptying, it suppresses the post-meal release of glucagon, and it promotes satiety. Native human amylin is a difficult research tool, though: it has a short half-life and a strong tendency to aggregate into insoluble fibrils. An earlier analog, pramlintide, addressed the aggregation problem but still required dosing at every meal.
A Long-Acting, Acylated Amylin Analog
Cagrilintide was developed by Novo Nordisk as a long-acting amylin analog. It uses the same fatty-acid acylation approach Novo Nordisk applied to semaglutide: a fatty-acid side chain lets the molecule bind circulating albumin, which slows its clearance and extends its half-life enough to support once-weekly dosing in research protocols. Structural changes to the peptide backbone also reduce the fibril-forming tendency of native amylin.
Amylin and Calcitonin Receptors in the Brainstem
Amylin receptors are not a single protein. They are formed when the calcitonin receptor pairs with one of three receptor-activity-modifying proteins (RAMPs), producing the AMY1, AMY2 and AMY3 receptor subtypes. Cagrilintide activates these amylin receptors and the calcitonin receptor itself, which is why it is often described as a non-selective amylin/calcitonin receptor agonist. A key site of action is the area postrema in the brainstem, a region outside the blood-brain barrier that relays satiety signals to appetite-regulating circuits in the hypothalamus.
Why It Is Paired With GLP-1 Agonists
GLP-1 receptor agonists such as semaglutide act on a separate receptor system, mainly through hypothalamic appetite centers and the gut. Because the amylin and GLP-1 pathways converge on appetite through different receptors and partly different brain regions, they are studied together for additive effects. That rationale underpins CagriSema, Novo Nordisk's fixed combination of cagrilintide and semaglutide, which in the Phase 3 REDEFINE-1 trial produced average weight loss of approximately 23% under the trial's treatment-policy estimand.
| Cagrilintide | GLP-1 receptor agonists | |
|---|---|---|
| Parent hormone | Amylin (from pancreatic beta cells) | GLP-1 (from intestinal L cells) |
| Receptor target | Amylin receptors (calcitonin receptor + RAMP) and calcitonin receptor | GLP-1 receptor |
| Key brain site | Area postrema (brainstem) | Hypothalamus and brainstem |
| Effect on insulin | No direct insulin-releasing effect | Glucose-dependent insulin release |
How This Differs From Retatrutide
Retatrutide activates the GIP, GLP-1 and glucagon receptors, all within the incretin and glucagon family, and does not act on amylin receptors. Cagrilintide works on an entirely separate receptor system. See our full Cagrilintide vs Retatrutide comparison for how the two compare.
- Amylin-receptor and calcitonin-receptor agonism research
- Appetite-regulation and satiety signaling studies
- Gastric-emptying research
- Combination research with GLP-1 receptor agonists
Cagrilintide mechanism questions
What receptor does Cagrilintide act on?
Cagrilintide activates amylin receptors, which are formed by the calcitonin receptor paired with a receptor-activity-modifying protein (RAMP), as well as the calcitonin receptor itself. A key site of action is the area postrema in the brainstem.
How is Cagrilintide different from semaglutide?
Semaglutide is a GLP-1 receptor agonist, while Cagrilintide is an amylin analog acting on amylin and calcitonin receptors. Both use fatty-acid acylation for a long half-life, but they act on separate receptor systems, which is why they are combined in CagriSema.
Why does Cagrilintide last longer than natural amylin?
Cagrilintide carries a fatty-acid side chain that binds circulating albumin, slowing its clearance, and its backbone is modified to reduce the fibril-forming tendency of native amylin. Together these changes support once-weekly dosing in research protocols.
Interested in Cagrilintide?
In stock at RM300 (S$100) for a 5mg vial. See the product page, or browse our other weight-loss and metabolic peptides.